Flexion Therapeutics (NSDQ:FLXN) today launched its Zilretta therapy designed to help patients manage pain associated with osteoarthritis of the knee.
The Burlington, Mass.-based company’s extended-release intra-articular injection combines a commonly administered, short-acting corticosteroid with a polylactic-co-glycolic acid matrix using Flexion’s microsphere technology.
Get the full story at our sister site, Drug Delivery Business News.
The post After FDA nod, Flexion launches osteoarthritis injection appeared first on MassDevice.